search
Back to results

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

Primary Purpose

Sleep Initiation and Maintenance Disorders, Depression

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Estrogen Replacement Therapy
Zolpidem
placebo
Sponsored by
Hadine Joffe, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Initiation and Maintenance Disorders focused on measuring Women, Menopause, Depression, Hot flash, Insomnia, Sleep Disruption, Estrogen Replacement Therapy

Eligibility Criteria

40 Years - 60 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Perimenopausal or postmenopausal status Surgical menopause or hysterectomy with one or both ovaries preserved if serum follicle stimulating hormone is greater than 20 IU/L Diagnosed with mild to moderate clinical depression Currently experiencing moderate to severe hot flashes Currently experiencing insomnia caused by nocturnal hot flashes Normal mammogram within the 2 years prior to study entry Willing to use an effective form of contraception throughout the study if perimenopausal and sexually active Exclusion Criteria: Current severe depression or history of severe depression within the 5 years prior to study entry Suicidal or homicidal ideation Psychotic symptoms History of any psychiatric disorder (e.g., psychosis, bipolar disorder, panic disorder, obsessive-compulsive disorder, or anorexia nervosa) History of any substance abuse (including alcohol abuse) within the 5 years prior to study entry Regular use of hormonal medications within the month prior to study entry Regular use of hypnotic drugs, antidepressants, or over-the-counter drugs known to influence hot flashes, sleep, or mood within the 2 weeks prior to study entry Intolerance to estrogen therapy or informed that estrogen therapy is medically inadvisable

Sites / Locations

  • MGH Center for Perinatal and Women's Mental Health

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

Arm Description

Participants will receive estrogen replacement therapy

Participants will receive treatment with zolpidem

Participants will receive treatment with placebo

Outcomes

Primary Outcome Measures

Improvement of mood; measured by the Montgomery-Asberg Depression Rating Scale

Secondary Outcome Measures

Quality of life indicators; measured by the Quality of Life Inventory

Full Information

First Posted
September 26, 2005
Last Updated
May 23, 2014
Sponsor
Hadine Joffe, MD
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00227942
Brief Title
Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia
Official Title
Understanding the Role That Hot Flashes and Sleep Disruption Play in the Effect of Estrogen Replacement Therapy on Mood in Perimenopausal and Postmenopausal Women
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
August 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Hadine Joffe, MD
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will evaluate the effectiveness of estrogen replacement therapy in treating depression in menopausal women with hot flashes and insomnia.
Detailed Description
Estrogen is a hormone that plays an important part in the development of the female reproductive system. During menopause, estrogen levels drop significantly. The drop in estrogen may cause physiologic and psychological changes in women; common symptoms include hot flashes, sweating, insomnia, and irritability. In addition, approximately 10% of menopausal women experience depression. Estrogen replacement therapy (ERT) is often prescribed to alleviate these symptoms. It is not known, however, exactly how ERT treats depression. It may indirectly decrease depression by alleviating insomnia associated with hot flashes, or it may directly improve mood and decrease depression by altering chemicals in the brain. The purpose of this study is to gain insight into how ERT treats depression and to develop strategies to reduce depression in menopausal women. In turn, these findings may help categorize populations of women whose depression should be treated with ERT versus nonhormonal therapies. In this 9-week study, participants will be randomly assigned to receive ERT, a sleeping pill, or placebo. Study visits will occur at baseline and Weeks 2, 4, 6, and 9; at each study visit, blood pressure will be monitored, and standardized psychological tests and questionnaires will be used to assess the participant's level of depression and reported quality of life outcomes. Blood will be drawn at baseline and Week 9 to measure estrogen and follicle stimulating hormone levels.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Initiation and Maintenance Disorders, Depression
Keywords
Women, Menopause, Depression, Hot flash, Insomnia, Sleep Disruption, Estrogen Replacement Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
86 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Participants will receive estrogen replacement therapy
Arm Title
2
Arm Type
Experimental
Arm Description
Participants will receive treatment with zolpidem
Arm Title
3
Arm Type
Placebo Comparator
Arm Description
Participants will receive treatment with placebo
Intervention Type
Drug
Intervention Name(s)
Estrogen Replacement Therapy
Other Intervention Name(s)
Climara
Intervention Description
17-b-Estradiol Patch, .05 mg/day; applied for 7 days
Intervention Type
Drug
Intervention Name(s)
Zolpidem
Other Intervention Name(s)
Ambien
Intervention Description
10 mg/day, po qhs
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo
Primary Outcome Measure Information:
Title
Improvement of mood; measured by the Montgomery-Asberg Depression Rating Scale
Time Frame
Measured at at baseline and Weeks 2, 4, 6, and 9
Secondary Outcome Measure Information:
Title
Quality of life indicators; measured by the Quality of Life Inventory
Time Frame
Measured at at baseline and Weeks 2, 4, 6, and 9

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Perimenopausal or postmenopausal status Surgical menopause or hysterectomy with one or both ovaries preserved if serum follicle stimulating hormone is greater than 20 IU/L Diagnosed with mild to moderate clinical depression Currently experiencing moderate to severe hot flashes Currently experiencing insomnia caused by nocturnal hot flashes Normal mammogram within the 2 years prior to study entry Willing to use an effective form of contraception throughout the study if perimenopausal and sexually active Exclusion Criteria: Current severe depression or history of severe depression within the 5 years prior to study entry Suicidal or homicidal ideation Psychotic symptoms History of any psychiatric disorder (e.g., psychosis, bipolar disorder, panic disorder, obsessive-compulsive disorder, or anorexia nervosa) History of any substance abuse (including alcohol abuse) within the 5 years prior to study entry Regular use of hormonal medications within the month prior to study entry Regular use of hypnotic drugs, antidepressants, or over-the-counter drugs known to influence hot flashes, sleep, or mood within the 2 weeks prior to study entry Intolerance to estrogen therapy or informed that estrogen therapy is medically inadvisable
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hadine Joffe, MD, MSC
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
MGH Center for Perinatal and Women's Mental Health
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02116
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
27648659
Citation
Galvan T, Camuso J, Sullivan K, Kim S, White D, Redline S, Joffe H. Association of estradiol with sleep apnea in depressed perimenopausal and postmenopausal women: a preliminary study. Menopause. 2017 Jan;24(1):112-117. doi: 10.1097/GME.0000000000000737.
Results Reference
derived
Links:
URL
http://www.womensmentalhealth.org
Description
Click here for the Massachusetts General Hospital Center for Women's Mental Health web site.

Learn more about this trial

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

We'll reach out to this number within 24 hrs